243 related articles for article (PubMed ID: 24059235)
21. Inhibition of farnesyltransferase: a rational approach to treat cancer?
Puntambekar DS; Giridhar R; Yadav MR
J Enzyme Inhib Med Chem; 2007 Apr; 22(2):127-40. PubMed ID: 17518338
[TBL] [Abstract][Full Text] [Related]
22. Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K; Hamilton AD; Sebti SM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
[TBL] [Abstract][Full Text] [Related]
23. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.
Cortes JE; Kurzrock R; Kantarjian HM
Semin Hematol; 2002 Jul; 39(3 Suppl 2):26-30. PubMed ID: 12214290
[TBL] [Abstract][Full Text] [Related]
24. Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.
Zheng H; Liu A; Liu B; Li M; Yu H; Luo X
Cancer Lett; 2010 Nov; 297(1):117-25. PubMed ID: 20554106
[TBL] [Abstract][Full Text] [Related]
25. The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.
Marcuzzi A; De Leo L; Decorti G; Crovella S; Tommasini A; Pontillo A
Pediatr Res; 2011 Jul; 70(1):78-82. PubMed ID: 21430599
[TBL] [Abstract][Full Text] [Related]
26. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
Cox AD
Drugs; 2001; 61(6):723-32. PubMed ID: 11398905
[TBL] [Abstract][Full Text] [Related]
27. Non-peptidic prenyltransferase inhibitors: diverse structural classes and surprising anti-cancer mechanisms.
Gibbs RA; Zahn TJ; Sebolt-Leopold JS
Curr Med Chem; 2001 Oct; 8(12):1437-65. PubMed ID: 11562276
[TBL] [Abstract][Full Text] [Related]
28. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model.
Capell BC; Olive M; Erdos MR; Cao K; Faddah DA; Tavarez UL; Conneely KN; Qu X; San H; Ganesh SK; Chen X; Avallone H; Kolodgie FD; Virmani R; Nabel EG; Collins FS
Proc Natl Acad Sci U S A; 2008 Oct; 105(41):15902-7. PubMed ID: 18838683
[TBL] [Abstract][Full Text] [Related]
29. A yeast-based genomic strategy highlights the cell protein networks altered by FTase inhibitor peptidomimetics.
Porcu G; Wilson C; Di Giandomenico D; Ragnini-Wilson A
Mol Cancer; 2010 Jul; 9():197. PubMed ID: 20653956
[TBL] [Abstract][Full Text] [Related]
30. Farnesyltransferase inhibitors.
Sebti SM; Adjei AA
Semin Oncol; 2004 Feb; 31(1 Suppl 1):28-39. PubMed ID: 14981578
[TBL] [Abstract][Full Text] [Related]
31. [Farnesyl transferase inhibitors--a novel agent for breast cancer].
Zhang M; Jiang D
Ai Zheng; 2006 Apr; 25(4):516-20. PubMed ID: 16613692
[TBL] [Abstract][Full Text] [Related]
32. In silico based structural analysis of some piperidine analogs as farnesyltransferase inhibitors.
Moorthy NS; Sousa SF; Ramos MJ; Fernandes PA
Med Chem; 2012 Sep; 8(5):853-64. PubMed ID: 22741784
[TBL] [Abstract][Full Text] [Related]
33. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
Jabbour E; Kantarjian H; Cortes J
Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
[TBL] [Abstract][Full Text] [Related]
34. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
[TBL] [Abstract][Full Text] [Related]
35. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.
Sebti SM; Hamilton AD
Expert Opin Investig Drugs; 2000 Dec; 9(12):2767-82. PubMed ID: 11093352
[TBL] [Abstract][Full Text] [Related]
36. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
Brunner TB; Hahn SM; Gupta AK; Muschel RJ; McKenna WG; Bernhard EJ
Cancer Res; 2003 Sep; 63(18):5656-68. PubMed ID: 14522880
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors.
Pan J; Yeung SC
Cancer Res; 2005 Oct; 65(20):9109-12. PubMed ID: 16230362
[TBL] [Abstract][Full Text] [Related]
38. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
Gordon LB; Kleinman ME; Massaro J; D'Agostino RB; Shappell H; Gerhard-Herman M; Smoot LB; Gordon CM; Cleveland RH; Nazarian A; Snyder BD; Ullrich NJ; Silvera VM; Liang MG; Quinn N; Miller DT; Huh SY; Dowton AA; Littlefield K; Greer MM; Kieran MW
Circulation; 2016 Jul; 134(2):114-25. PubMed ID: 27400896
[TBL] [Abstract][Full Text] [Related]
39. Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity.
Reid TS; Beese LS
Biochemistry; 2004 Jun; 43(22):6877-84. PubMed ID: 15170324
[TBL] [Abstract][Full Text] [Related]
40. Progeria, the nucleolus and farnesyltransferase inhibitors.
Mehta IS; Bridger JM; Kill IR
Biochem Soc Trans; 2010 Feb; 38(Pt 1):287-91. PubMed ID: 20074076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
